29 October 2021 - - The US government has purchased 50m more doses of US-based pharmaceutical company Pfizer Inc's (NYSE: PFE) and German biotechnology company BioNTech SE's (NASDAQ: BNTX)
COVID-19 vaccine, the companies said.

The US will receive these additional doses to continue to support preparedness for pediatric vaccinations, including securing vaccines for children under five years of age, should they receive regulatory authorization.

The companies expect to deliver all these doses by April 30, 2022.

With this order, the US government has exercised its final purchase option under its existing US supply agreement with the companies, bringing the total number of Pfizer-BioNTech COVID-19 Vaccine doses secured under the agreement since the start of the pandemic to 600 m spanning doses for adults and adolescents, and children.

Separately, Pfizer and BioNTech have agreed to provide a total of 1bn doses to the US government at a not-for-profit price for donation to low- and lower-middle-income countries.

Pfizer and BioNTech submitted a request earlier this month to the US Food and Drug Administration for Emergency Use Authorization of their COVID-19 vaccine in children 5 to